Although increased GLUT‐1 expression is associated with pancreatic cancer aggressiveness, and invasiveness 17, 19, and treatment with Tris reduced aggressiveness, we fully expected that GLUT‐1 would be elevated as a response to compensate for the increase in buffering and acid neutralization. Here, SLC2A1 is linked to pancreatic neoplasm.